Actively Recruiting
Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
Led by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Updated on 2026-04-14
40
Participants Needed
1
Research Sites
43 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.
CONDITIONS
Official Title
Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with confirmed immune-mediated thrombotic thrombocytopenic purpura (iTTP) defined by ADAMTS13 activity <10% with anti-ADAMTS13 antibodies detected
- Aged 18 years or older
- Male and female patients
- Treated with daratumumab for iTTP
You will not qualify if you...
- Patients unwilling or unable to provide informed consent
- Follow-up less than 6 months after daratumumab administration
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
Milan, Italy
Actively Recruiting
Research Team
J
Juri A Giannotta, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here